Back to today’s briefing

Story perspectives

16-Year-Old's Death Linked to Sarepta's Gene Therapy

3/18/2025

26 2

Summary

Story summary

A tragic incident has emerged as Sarepta Therapeutics confirmed the death of a 16-year-old boy from acute liver failure after receiving their gene therapy, Elevidys, for Duchenne muscular dystrophy. This marks the first death associated with Elevidys, which has been administered to over 800 patients. The company suggested a recent cytomegalovirus infection might have played a role, leading to a 23% drop in Sarepta's stock.

1 of 1

Story summary

A tragic incident has emerged as Sarepta Therapeutics confirmed the death of a 16-year-old boy from acute liver failure after receiving their gene therapy, Elevidys, for Duchenne muscular dystrophy. This marks the first death associated with Elevidys, which has been administered to over 800 patients. The company suggested a recent cytomegalovirus infection might have played a role, leading to a 23% drop in Sarepta's stock.